Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).
Identifieur interne : 000E23 ( Main/Corpus ); précédent : 000E22; suivant : 000E24Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).
Auteurs : Camilla Evangelisti ; Cecilia Evangelisti ; Francesca Chiarini ; Annalisa Lonetti ; Francesca Buontempo ; Daniela Bressanin ; Alessandra Cappellini ; Ester Orsini ; James A. Mccubrey ; Alberto M. MartelliSource :
- International journal of oncology [ 1791-2423 ] ; 2014.
English descriptors
- KwdEn :
- Antineoplastic Agents (pharmacology), Antineoplastic Agents (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (MeSH), Humans (MeSH), Molecular Targeted Therapy (MeSH), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (drug therapy), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (pathology), Signal Transduction (drug effects), TOR Serine-Threonine Kinases (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : TOR Serine-Threonine Kinases.
- chemical , pharmacology : Antineoplastic Agents.
- chemical , therapeutic use : Antineoplastic Agents.
- drug effects : Signal Transduction.
- drug therapy : Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.
- pathology : Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.
- Antineoplastic Combined Chemotherapy Protocols, Humans, Molecular Targeted Therapy.
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous neoplastic disorder of immature hematopoietic precursors committed to the T-cell lineage. T-ALL comprises about 15% of pediatric and 25% of adult ALL cases. Even if the prognosis of T-ALL has improved especially in the childhood due to the use of new intensified treatment protocols, the outcome of relapsed patients who are resistant to conventional chemotherapeutic drugs or who relapse is still poor. For this reason, there is a need for novel and less toxic targeted therapies against signaling pathways aberrantly activated in T-ALL, such as the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR). Small molecules designed to target key components of this signaling axis have proven their efficacy both in vitro and in vivo in pre-clinical settings of T-ALL. In particular, different classes of mTOR inhibitors have been disclosed by pharmaceutical companies, and they are currently being tested in clinical trials for treating T-ALL patients. One of the most promising approaches for the treatment of T-ALL seems to be the combination of mTOR inhibitors with traditional chemotherapeutic agents. This could lead to a lower drug dosage that may circumvent the systemic side effects of chemotherapeutics. In this review, we focus on the different classes of mTOR inhibitors that will possibly have an impact on the therapeutic arsenal we have at our disposal against T-ALL.
DOI: 10.3892/ijo.2014.2525
PubMed: 24968804
Links to Exploration step
pubmed:24968804Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).</title><author><name sortKey="Evangelisti, Camilla" sort="Evangelisti, Camilla" uniqKey="Evangelisti C" first="Camilla" last="Evangelisti">Camilla Evangelisti</name><affiliation><nlm:affiliation>Institute of Molecular Genetics, National Research Council, Rizzoli Orthopedic Institute, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Evangelisti, Cecilia" sort="Evangelisti, Cecilia" uniqKey="Evangelisti C" first="Cecilia" last="Evangelisti">Cecilia Evangelisti</name><affiliation><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Chiarini, Francesca" sort="Chiarini, Francesca" uniqKey="Chiarini F" first="Francesca" last="Chiarini">Francesca Chiarini</name><affiliation><nlm:affiliation>Institute of Molecular Genetics, National Research Council, Rizzoli Orthopedic Institute, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Lonetti, Annalisa" sort="Lonetti, Annalisa" uniqKey="Lonetti A" first="Annalisa" last="Lonetti">Annalisa Lonetti</name><affiliation><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Buontempo, Francesca" sort="Buontempo, Francesca" uniqKey="Buontempo F" first="Francesca" last="Buontempo">Francesca Buontempo</name><affiliation><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bressanin, Daniela" sort="Bressanin, Daniela" uniqKey="Bressanin D" first="Daniela" last="Bressanin">Daniela Bressanin</name><affiliation><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Cappellini, Alessandra" sort="Cappellini, Alessandra" uniqKey="Cappellini A" first="Alessandra" last="Cappellini">Alessandra Cappellini</name><affiliation><nlm:affiliation>Department of Human Social and Health Sciences, University of Cassino, Cassino, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Orsini, Ester" sort="Orsini, Ester" uniqKey="Orsini E" first="Ester" last="Orsini">Ester Orsini</name><affiliation><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Mccubrey, James A" sort="Mccubrey, James A" uniqKey="Mccubrey J" first="James A" last="Mccubrey">James A. Mccubrey</name><affiliation><nlm:affiliation>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Martelli, Alberto M" sort="Martelli, Alberto M" uniqKey="Martelli A" first="Alberto M" last="Martelli">Alberto M. Martelli</name><affiliation><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24968804</idno><idno type="pmid">24968804</idno><idno type="doi">10.3892/ijo.2014.2525</idno><idno type="wicri:Area/Main/Corpus">000E23</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000E23</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).</title><author><name sortKey="Evangelisti, Camilla" sort="Evangelisti, Camilla" uniqKey="Evangelisti C" first="Camilla" last="Evangelisti">Camilla Evangelisti</name><affiliation><nlm:affiliation>Institute of Molecular Genetics, National Research Council, Rizzoli Orthopedic Institute, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Evangelisti, Cecilia" sort="Evangelisti, Cecilia" uniqKey="Evangelisti C" first="Cecilia" last="Evangelisti">Cecilia Evangelisti</name><affiliation><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Chiarini, Francesca" sort="Chiarini, Francesca" uniqKey="Chiarini F" first="Francesca" last="Chiarini">Francesca Chiarini</name><affiliation><nlm:affiliation>Institute of Molecular Genetics, National Research Council, Rizzoli Orthopedic Institute, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Lonetti, Annalisa" sort="Lonetti, Annalisa" uniqKey="Lonetti A" first="Annalisa" last="Lonetti">Annalisa Lonetti</name><affiliation><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Buontempo, Francesca" sort="Buontempo, Francesca" uniqKey="Buontempo F" first="Francesca" last="Buontempo">Francesca Buontempo</name><affiliation><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bressanin, Daniela" sort="Bressanin, Daniela" uniqKey="Bressanin D" first="Daniela" last="Bressanin">Daniela Bressanin</name><affiliation><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Cappellini, Alessandra" sort="Cappellini, Alessandra" uniqKey="Cappellini A" first="Alessandra" last="Cappellini">Alessandra Cappellini</name><affiliation><nlm:affiliation>Department of Human Social and Health Sciences, University of Cassino, Cassino, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Orsini, Ester" sort="Orsini, Ester" uniqKey="Orsini E" first="Ester" last="Orsini">Ester Orsini</name><affiliation><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Mccubrey, James A" sort="Mccubrey, James A" uniqKey="Mccubrey J" first="James A" last="Mccubrey">James A. Mccubrey</name><affiliation><nlm:affiliation>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Martelli, Alberto M" sort="Martelli, Alberto M" uniqKey="Martelli A" first="Alberto M" last="Martelli">Alberto M. Martelli</name><affiliation><nlm:affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">International journal of oncology</title><idno type="eISSN">1791-2423</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (pharmacology)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Antineoplastic Combined Chemotherapy Protocols (MeSH)</term><term>Humans (MeSH)</term><term>Molecular Targeted Therapy (MeSH)</term><term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)</term><term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (pathology)</term><term>Signal Transduction (drug effects)</term><term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>TOR Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Humans</term><term>Molecular Targeted Therapy</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous neoplastic disorder of immature hematopoietic precursors committed to the T-cell lineage. T-ALL comprises about 15% of pediatric and 25% of adult ALL cases. Even if the prognosis of T-ALL has improved especially in the childhood due to the use of new intensified treatment protocols, the outcome of relapsed patients who are resistant to conventional chemotherapeutic drugs or who relapse is still poor. For this reason, there is a need for novel and less toxic targeted therapies against signaling pathways aberrantly activated in T-ALL, such as the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR). Small molecules designed to target key components of this signaling axis have proven their efficacy both in vitro and in vivo in pre-clinical settings of T-ALL. In particular, different classes of mTOR inhibitors have been disclosed by pharmaceutical companies, and they are currently being tested in clinical trials for treating T-ALL patients. One of the most promising approaches for the treatment of T-ALL seems to be the combination of mTOR inhibitors with traditional chemotherapeutic agents. This could lead to a lower drug dosage that may circumvent the systemic side effects of chemotherapeutics. In this review, we focus on the different classes of mTOR inhibitors that will possibly have an impact on the therapeutic arsenal we have at our disposal against T-ALL.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24968804</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2014</Year><Month>07</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1791-2423</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of oncology</Title><ISOAbbreviation>Int J Oncol</ISOAbbreviation></Journal><ArticleTitle>Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).</ArticleTitle><Pagination><MedlinePgn>909-18</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3892/ijo.2014.2525</ELocationID><Abstract><AbstractText>T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous neoplastic disorder of immature hematopoietic precursors committed to the T-cell lineage. T-ALL comprises about 15% of pediatric and 25% of adult ALL cases. Even if the prognosis of T-ALL has improved especially in the childhood due to the use of new intensified treatment protocols, the outcome of relapsed patients who are resistant to conventional chemotherapeutic drugs or who relapse is still poor. For this reason, there is a need for novel and less toxic targeted therapies against signaling pathways aberrantly activated in T-ALL, such as the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR). Small molecules designed to target key components of this signaling axis have proven their efficacy both in vitro and in vivo in pre-clinical settings of T-ALL. In particular, different classes of mTOR inhibitors have been disclosed by pharmaceutical companies, and they are currently being tested in clinical trials for treating T-ALL patients. One of the most promising approaches for the treatment of T-ALL seems to be the combination of mTOR inhibitors with traditional chemotherapeutic agents. This could lead to a lower drug dosage that may circumvent the systemic side effects of chemotherapeutics. In this review, we focus on the different classes of mTOR inhibitors that will possibly have an impact on the therapeutic arsenal we have at our disposal against T-ALL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Evangelisti</LastName><ForeName>Camilla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Molecular Genetics, National Research Council, Rizzoli Orthopedic Institute, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evangelisti</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiarini</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Molecular Genetics, National Research Council, Rizzoli Orthopedic Institute, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lonetti</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buontempo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bressanin</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cappellini</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Human Social and Health Sciences, University of Cassino, Cassino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orsini</LastName><ForeName>Ester</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCubrey</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martelli</LastName><ForeName>Alberto M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Int J Oncol</MedlineTA><NlmUniqueID>9306042</NlmUniqueID><ISSNLinking>1019-6439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054218" MajorTopicYN="N">Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>04</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24968804</ArticleId><ArticleId IdType="doi">10.3892/ijo.2014.2525</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E23 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000E23 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:24968804
|texte= Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:24968804" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |